Table 2.
NSCLC Pembrolizumab -treated cohort. For each patient the (i) number of cycles of pembrolizumab therapy performed, (ii) time of treatment failure (TTF), (iii) overall survival (OS), (iv) PD-L1 expression levels; (v) iRECIST classification for the radiological assessments (RA), are reported: complete response (iCR), partial response (iPR), stable disease (iSD), unconfirmed progressive disease (iUPD), confirmed progressive disease (iCPD) and hyper-progression (iHP). Patients considered responders are highlighted in grey.
| Subject Number | N° Cycles | TTF (Week) |
OS (Week) |
PD-L1 | 1 RA | 2 RA | 3 RA | 4 RA | 5 RA | 6 RA | 7 RA | 8 RA | 9 RA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MetL22 | 35 | 115+ | 118+ | 80 | iPR | iPR | iPR | iPR | iPR | iSD | iSD | iUPD | iSD |
| MetL23 | 36 | 115+ | 116+ | 60 | iPR | iPR | iCR | iCR | iCR | iSD | iSD | iSD | |
| MetL25 | 33 | 106+ | 109+ | 70 | iSD | iSD | iSD | iSD | iSD | iSD | iSD | iSD | iSD |
| MetL27 | 3 | 6 | 14 | 80 | |||||||||
| MetL28 | 8 | 24 | 39 | 70 | iPR | iUPD | iCPD | ||||||
| MetL31 | 3 | 8 | 10 | 70 | |||||||||
| MetL35 | 11 | 37 | 39 | 70 | iSD | iUPD | iUPD | iCPD | |||||
| MetL38 | 26 | 82+ | 87+ | 60 | iPR | iPR | iSD | iSD | iSD | ||||
| MetL43 | 1 | 5 | 5 | 60 | |||||||||
| MetL46 | 17 | 62+ | 66+ | 60 | iUPD | iPR | iPR | iPR | iPR | ||||
| MetL47 | 17 | 54+ | 56+ | 80 | iPR | iUPD | iSD | ||||||
| MetL51 | 14 | 45+ | 49+ | 70 | iPR | iPR | iSD | ||||||
| MetL55 | 1 | 1 | 1 | 80 | |||||||||
| MetL56 | 3 | 9 | 17 | 90 | iPD | ||||||||
| MetL59 | 3 | 6 | xx | 80 | iPD | ||||||||
| MetL60 | 5 | 15 | 19 | 60 | iSD | ||||||||
| MetL63 | 4 | 20 | 23 | 50 | iUPD | iCPD | |||||||
| MetL65 | 8 | 22 | 30+ | 90 | iPR | iUPD | |||||||
| MetL66 | 7 | 26 | 90 | iUPD | iCPD |